Erasca Reports Negative Phase 1 Trial Data, Shares Drop 37%
Erasca (ERAS) shares fell approximately 37% in extended trading after releasing early Phase 1 trial data for its solid tumor candidate ERAS-0015. The data likely raised concerns about the drug's efficacy or safety, impacting investor sentiment. This development may affect competition in the RAS-targeting cancer drug space, particularly with Revolution Medicines (RVMD).
Topics: biotech cancer drugs clinical trials RAS mutations stock price movement